An2 Therapeutics Stock Performance
| ANTX Stock | USD 1.67 0.30 21.90% |
On a scale of 0 to 100, AN2 Therapeutics holds a performance score of 13. The firm owns a Beta (Systematic Risk) of 0.97, which signifies possible diversification benefits within a given portfolio. AN2 Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, AN2 Therapeutics is expected to follow. Please check AN2 Therapeutics' value at risk, and the relationship between the standard deviation and kurtosis , to make a quick decision on whether AN2 Therapeutics' current price history will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in AN2 Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, AN2 Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Anthem Sports Entertainment acquires Canadian specialty channels Hollywood Suite | 09/25/2024 |
2 | Acquisition by Day Lucy of 27500 shares of AN2 Therapeutics subject to Rule 16b-3 | 09/27/2024 |
3 | Anthem Blue Cross and Blue Shield Foundation and McShin Foundation Expand Support for Virginians in Recovery | 10/17/2024 |
4 | Ground Media And GLAAD Named Finalists In Four Categories At Anthem Awards For Groundbreaking Here We Are Campaign | 10/28/2024 |
5 | Michael Strahan responds to National Anthem backlash | 11/13/2024 |
6 | Acquisition by Eric Easom of 50000 shares of AN2 Therapeutics at 0.9994 subject to Rule 16b-3 | 11/18/2024 |
7 | An2 therapeutics CEO Eric Easom acquires 49,970 in stock | 11/19/2024 |
8 | Native Forward Wins Anthem Award for Social Impact | 11/20/2024 |
9 | An2 therapeutics director Robin Shane Readnour acquires shares worth 213,127 | 11/21/2024 |
10 | Disposition of 83337 shares by Aziz Kabeer of AN2 Therapeutics at 16.28 subject to Rule 16b-3 | 11/22/2024 |
11 | Acquisition by Joseph Zakrzewski of 2000 shares of AN2 Therapeutics at 1.4 subject to Rule 16b-3 | 11/27/2024 |
| Begin Period Cash Flow | 27.2 M |
AN2 |
AN2 Therapeutics Relative Risk vs. Return Landscape
If you would invest 110.00 in AN2 Therapeutics on September 1, 2024 and sell it today you would earn a total of 57.00 from holding AN2 Therapeutics or generate 51.82% return on investment over 90 days. AN2 Therapeutics is currently generating 0.7567% in daily expected returns and assumes 4.5395% risk (volatility on return distribution) over the 90 days horizon. In different words, 40% of stocks are less volatile than AN2, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AN2 Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AN2 Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AN2 Therapeutics, and traders can use it to determine the average amount a AN2 Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1667
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ANTX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.54 actual daily | 40 60% of assets are more volatile |
Expected Return
| 0.76 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average AN2 Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AN2 Therapeutics by adding it to a well-diversified portfolio.
AN2 Therapeutics Fundamentals Growth
AN2 Stock prices reflect investors' perceptions of the future prospects and financial health of AN2 Therapeutics, and AN2 Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AN2 Stock performance.
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.43 | ||||
| Current Valuation | (54.31 M) | ||||
| Shares Outstanding | 29.88 M | ||||
| Price To Earning | 3.96 X | ||||
| Price To Book | 0.47 X | ||||
| EBITDA | 4.9 M | ||||
| Net Income | (64.73 M) | ||||
| Cash And Equivalents | 113.39 M | ||||
| Cash Per Share | 5.84 X | ||||
| Total Debt | 14.04 M | ||||
| Current Ratio | 28.17 X | ||||
| Book Value Per Share | 4.19 X | ||||
| Cash Flow From Operations | (53.29 M) | ||||
| Earnings Per Share | (1.99) X | ||||
| Market Capitalization | 40.93 M | ||||
| Total Asset | 138.74 M | ||||
| Retained Earnings | (154.46 M) | ||||
| Working Capital | 96.46 M | ||||
About AN2 Therapeutics Performance
Evaluating AN2 Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AN2 Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AN2 Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.47) | (0.49) | |
| Return On Capital Employed | (0.56) | (0.59) | |
| Return On Assets | (0.47) | (0.49) | |
| Return On Equity | (0.52) | (0.49) |
Things to note about AN2 Therapeutics performance evaluation
Checking the ongoing alerts about AN2 Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AN2 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AN2 Therapeutics may become a speculative penny stock | |
| AN2 Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (64.73 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (53.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AN2 Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 22.0% of the company shares are held by company insiders | |
| Latest headline from investing.com: Acquisition by Joseph Zakrzewski of 2000 shares of AN2 Therapeutics at 1.4 subject to Rule 16b-3 |
- Analyzing AN2 Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AN2 Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining AN2 Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AN2 Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of AN2 Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AN2 Therapeutics' stock. These opinions can provide insight into AN2 Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.